nach oben

Erschienen in:

01.04.2014 | Original Article

Circulating chemerin decreases in response to a combined strength and endurance training

verfasst von: Tsvetan Stefanov, Matthias Blüher, Anna Vekova, Iveta Bonova, Stanislav Tzvetkov, Dimo Kurktschiev, Theodora Temelkova-Kurktschiev

Erschienen in: Endocrine | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Chemerin is an adipokine that may mediate the link between obesity, inflammation, insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. In this study, we examined the association between chemerin and various cardiometabolic risk factors in cross-sectional setting and tested the hypothesis that a 6-month combined exercise program decreases serum chemerin in overweight or obese, non-diabetic individuals. Serum chemerin concentration was measured in a cross-sectional analysis including 98 individuals with a wide range of age and body mass index (BMI). In addition, chemerin was measured in 79 sedentary, overweight or obese, non-diabetic individuals who completed a 6-month combined endurance and resistance exercise program (CEP, n = 51) or served as controls (C, n = 28). Chemerin was significantly associated with total cholesterol (p = 0.04), triglycerides (p < 0.001), fasting insulin (p < 0.001), homeostasis model assessment of insulin resistance (HOMA-IR, p < 0.001), systolic blood pressure (p = 0.04), highly sensitive C-reactive protein (p = 0.03), leucocytes count (p = 0.047), and leptin (p = 0.008) independently of age and BMI. In multiple regression analysis, chemerin was an independent determinant of HOMA-IR. As a result of the 6-month training program, serum chemerin decreased significantly in CEP group (−13.8 ± 13.2 ng/ml, p < 0.001). A significant association between the changes in chemerin and improved HOMA-IR were found even after adjustment for changes in waist circumference. Among non-diabetic individuals serum chemerin was associated with various cardiometabolic risk factors independently of BMI. In addition, the 6-month combined strength and endurance training program led to a significant reduction in circulating chemerin levels in overweight or obese individuals.

T. Temelkova-Kurktschiev, T. Stefanov, Lifestyle and genetics in obesity and type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 120(1), 1–6 (2012)PubMed

P. Hossain, B. Kawar, M. El Nahas, Obesity and diabetes in the developing world—a growing challenge. N. Engl. J. Med. 356(3), 213–215 (2007)PubMedCrossRef

H.E. Lebovitz, M.A. Banerji, Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 28(9), 2322–2325 (2005)PubMedCrossRef

E.E. Kershaw, J.S. Flier, Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548–2556 (2004)PubMedCrossRef

M. Bluher, Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117(6), 241–250 (2009)PubMedCrossRef

G.R. Hajer, T.W. van Haeften, F.L. Visseren, Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29(24), 2959–2971 (2008)PubMedCrossRef

K. Bozaoglu, K. Bolton, J. McMillan, P. Zimmet, J. Jowett, G. Collier, K. Walder, D. Segal, Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148(10), 4687–4694 (2007)PubMedCrossRef

K.B. Goralski, T.C. McCarthy, E.A. Hanniman, B.A. Zabel, E.C. Butcher, S.D. Parlee, S. Muruganandan, C.J. Sinal, Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 282(38), 28175–28188 (2007)PubMedCrossRef

M. Takahashi, Y. Takahashi, K. Takahashi, F.N. Zolotaryov, K.S. Hong, R. Kitazawa, K. Iida, Y. Okimura, H. Kaji, S. Kitazawa, M. Kasuga, K. Chihara, Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3–L1 adipocytes. FEBS Lett. 582(5), 573–578 (2008)PubMedCrossRef

10.

H. Sell, J. Laurencikiene, A. Taube, K. Eckardt, A. Cramer, A. Horrighs, P. Arner, J. Eckel, Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 58(12), 2731–2740 (2009)PubMedCentralPubMedCrossRef

11.

M.C. Ernst, M. Issa, K.B. Goralski, C.J. Sinal, Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 151(5), 1998–2007 (2010)PubMedCrossRef

12.

M. Becker, K. Rabe, C. Lebherz, J. Zugwurst, B. Goke, K.G. Parhofer, M. Lehrke, U.C. Broedl, Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 59(11), 2898–2903 (2010)PubMedCentralPubMedCrossRef

13.

J. Weigert, M. Neumeier, J. Wanninger, M. Filarsky, S. Bauer, R. Wiest, S. Farkas, M.N. Scherer, A. Schaffler, C. Aslanidis, J. Scholmerich, C. Buechler, Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. (Oxf) 72(3), 342–348 (2010)CrossRef

14.

K. Bozaoglu, D. Segal, K.A. Shields, N. Cummings, J.E. Curran, A.G. Comuzzie, M.C. Mahaney, D.L. Rainwater, J.L. VandeBerg, J.W. MacCluer, G. Collier, J. Blangero, K. Walder, J.B. Jowett, Chemerin is associated with metabolic syndrome phenotypes in a Mexican–American population. J. Clin. Endocrinol. Metab. 94(8), 3085–3088 (2009)PubMedCentralPubMedCrossRef

15.

R. Chakaroun, M. Raschpichler, N. Kloting, A. Oberbach, G. Flehmig, M. Kern, M.R. Schon, E. Shang, T. Lohmann, M. Dressler, M. Fasshauer, M. Stumvoll, M. Bluher, Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism (2011). doi:10.1016/j.metabol.2011.10.008

16.

T. Sledzinski, J. Korczynska, A. Hallmann, L. Kaska, M. Proczko-Markuszewska, T. Stefaniak, M. Sledzinski, J. Swierczynski, The increase of serum chemerin concentration is mainly associated with the increase of BMI in obese, non-diabetic subjects. J. Endocrinol. Invest. (2012). doi:10.3275/8770

17.

A. Tonjes, M. Fasshauer, J. Kratzsch, M. Stumvoll, M. Bluher, Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 5(11), e13911 (2010)PubMedCentralPubMedCrossRef

18.

M. Yang, G. Yang, J. Dong, Y. Liu, H. Zong, H. Liu, G. Boden, L. Li, Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J. Investig. Med. 58(7), 883–886 (2010)PubMed

19.

S.H. Chu, M.K. Lee, K.Y. Ahn, J.A. Im, M.S. Park, D.C. Lee, J.Y. Jeon, J.W. Lee, Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 7(4), e34710 (2012)PubMedCentralPubMedCrossRef

20.

N. Kloting, M. Fasshauer, A. Dietrich, P. Kovacs, M.R. Schon, M. Kern, M. Stumvoll, M. Bluher, Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299(3), E506–E515 (2010)PubMedCrossRef

21.

A.A. Roman, S.D. Parlee, C.J. Sinal, Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine 42(2), 243–251 (2012)PubMedCrossRef

22.

D.M. Ouwens, M. Bekaert, B. Lapauw, Y. Van Nieuwenhove, S. Lehr, S. Hartwig, P. Calders, J.M. Kaufman, H. Sell, J. Eckel, J.B. Ruige, Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch. Physiol. Biochem. 118(3), 135–138 (2012)PubMedCrossRef

23.

S.N. Blair, J.N. Morris, Healthy hearts–and the universal benefits of being physically active: physical activity and health. Ann. Epidemiol. 19(4), 253–256 (2009)PubMedCrossRef

24.

T. Stefanov, A. Vekova, I. Bonova, S. Tzvetkov, D. Kurktschiev, M. Bluher, T. Temelkova-Kurktschiev, Effects of supervised vs non-supervised combined aerobic and resistance exercise programme on cardiometabolic risk factors. Cent. Eur. J. Public Health 21(1), 239–243 (2013)

25.

M. Venojarvi, N. Wasenius, S. Manderoos, O.J. Heinonen, M. Hernelahti, H. Lindholm, J. Surakka, J. Lindstrom, S. Aunola, M. Atalay, J.G. Eriksson, Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Ann. Med. (2012). doi:10.3109/07853890.2012.727020

26.

B.E. Ainsworth, W.L. Haskell, S.D. Herrmann, N. Meckes, D.R. Bassett Jr., C. Tudor-Locke, J.L. Greer, J. Vezina, M.C. Whitt-Glover, A.S. Leon, Compendium of Physical Activities: a second update of codes and MET values. Med. Sci. Sports Exerc. 43(8), 1575–1581 (2011)PubMedCrossRef

27.

V. Noonan, E. Dean, Submaximal exercise testing: clinical application and interpretation. Phys. Ther. 80(8), 782–807 (2000)PubMed

28.

C. Foster, A.S. Jackson, M.L. Pollock, M.M. Taylor, J. Hare, S.M. Sennett, J.L. Rod, M. Sarwar, D.H. Schmidt, Generalized equations for predicting functional capacity from treadmill performance. Am. Heart J. 107(6), 1229–1234 (1984)PubMedCrossRef

29.

D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7), 412–419 (1985)PubMedCrossRef

30.

P. Zimmet, D. Magliano, Y. Matsuzawa, G. Alberti, J. Shaw, The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 12(6), 295–300 (2005)PubMedCrossRef

31.

M. Lehrke, A. Becker, M. Greif, R. Stark, R.P. Laubender, F. von Ziegler, C. Lebherz, J. Tittus, M. Reiser, C. Becker, B. Goke, A.W. Leber, K.G. Parhofer, U.C. Broedl, Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol. 161(2), 339–344 (2009)PubMedCrossRef

32.

D. Stejskal, M. Karpisek, Z. Hanulova, M. Svestak, Chemerin is an independent marker of the metabolic syndrome in a Caucasian population–a pilot study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 152(2), 217–221 (2008)PubMedCrossRef

33.

H.Y. Shin, D.C. Lee, S.H. Chu, J.Y. Jeon, M.K. Lee, J.A. Im, J.W. Lee, Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin. Endocrinol. (Oxf) (2011). doi:10.1111/j.1365-2265.2011.04217.x

34.

B. Dong, W. Ji, Y. Zhang, Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern. Med. 50(10), 1093–1097 (2011)PubMedCrossRef

35.

V. Catalan, J. Gomez-Ambrosi, A. Rodriguez, B. Ramirez, F. Rotellar, V. Valenti, C. Silva, M.J. Gil, J. Salvador, G. Fruhbeck, Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-alpha stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg. Obes. Relat. Dis. (2011). doi:10.1016/j.soard.2011.11.001

36.

S. Bauer, M. Bala, A. Kopp, K. Eisinger, A. Schmid, S. Schneider, M. Neumeier, C. Buechler, Adipocyte chemerin release is induced by insulin without being translated to higher levels in vivo. Eur. J. Clin. Invest. 42(11), 1213–1220 (2012)PubMedCrossRef

37.

B.K. Tan, J. Chen, S. Farhatullah, R. Adya, J. Kaur, D. Heutling, K.C. Lewandowski, J.P. O’Hare, H. Lehnert, H.S. Randeva, Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 58(9), 1971–1977 (2009)PubMedCentralPubMedCrossRef

38.

M.C. Ernst, C.J. Sinal, Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol. Metab. 21(11), 660–667 (2010)PubMedCrossRef

39.

M. Bluher, A. Rudich, N. Kloting, R. Golan, Y. Henkin, E. Rubin, D. Schwarzfuchs, Y. Gepner, M.J. Stampfer, M. Fiedler, J. Thiery, M. Stumvoll, I. Shai, Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 35(2), 342–349 (2012)PubMedCentralPubMedCrossRef

40.

H. Sell, A. Divoux, C. Poitou, A. Basdevant, J.L. Bouillot, P. Bedossa, J. Tordjman, J. Eckel, K. Clement, Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 95(6), 2892–2896 (2010)PubMedCrossRef

41.

C. Ress, A. Tschoner, J. Engl, A. Klaus, H. Tilg, C.F. Ebenbichler, J.R. Patsch, S. Kaser, Effect of bariatric surgery on circulating chemerin levels. Eur. J. Clin. Invest. 40(3), 277–280 (2010)PubMedCrossRef

42.

T.A. Lakka, D.E. Laaksonen, H.M. Lakka, N. Mannikko, L.K. Niskanen, R. Rauramaa, J.T. Salonen, Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med. Sci. Sports Exerc. 35(8), 1279–1286 (2003)PubMedCrossRef

43.

P.T. Katzmarzyk, T.S. Church, S.N. Blair, Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch. Intern. Med. 164(10), 1092–1097 (2004)PubMedCrossRef

44.

D.C. Lee, X. Sui, T.S. Church, I.M. Lee, S.N. Blair, Associations of cardiorespiratory fitness and obesity with risks of impaired fasting glucose and type 2 diabetes in men. Diabetes Care 32(2), 257–262 (2009)PubMedCentralPubMedCrossRef

45.

D. Stensvold, A.E. Tjonna, E.A. Skaug, S. Aspenes, T. Stolen, U. Wisloff, S.A. Slordahl, Strength training versus aerobic interval training to modify risk factors of metabolic syndrome. J. Appl. Physiol. 108(4), 804–810 (2010)PubMedCrossRef

46.

C.A. Libardi, G.V. De Souza, C.R. Cavaglieri, V.A. Madruga, M.P. Chacon-Mikahil, Effect of resistance, endurance, and concurrent training on TNF-alpha, IL-6, and CRP. Med. Sci. Sports Exerc. 44(1), 50–56 (2012)PubMedCrossRef

47.

L.A. Bateman, C.A. Slentz, L.H. Willis, A.T. Shields, L.W. Piner, C.W. Bales, J.A. Houmard, W.E. Kraus, Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise-STRRIDE-AT/RT). Am. J. Cardiol. 108(6), 838–844 (2011)PubMedCentralPubMedCrossRef

48.

C.A. Slentz, L.A. Bateman, L.H. Willis, A.T. Shields, C.J. Tanner, L.W. Piner, V.H. Hawk, M.J. Muehlbauer, G.P. Samsa, R.C. Nelson, K.M. Huffman, C.W. Bales, J.A. Houmard, W.E. Kraus, Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am. J. Physiol. Endocrinol. Metab. 301(5), E1033–E1039 (2011)PubMedCentralPubMedCrossRef

Titel: Circulating chemerin decreases in response to a combined strength and endurance training
verfasst von: Tsvetan Stefanov
Matthias Blüher
Anna Vekova
Iveta Bonova
Stanislav Tzvetkov
Dimo Kurktschiev
Theodora Temelkova-Kurktschiev
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-013-0003-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features

Prostate cancer treated with androgen deprivation therapy has consequences for bone

Creatine supplementation and aging musculoskeletal health

Depression-like behavior in subclinical hypothyroidism rat induced by hemi-thyroid electrocauterization

Association of the ATM gene polymorphisms with papillary thyroid cancer